SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Maksymowych WP, Landewe R. Imaging in ankylosing spondylitis. Best Pract Res Clin Rheumatol 2006; 20: 50719.
  • 2
    Braun J, Baraliakos X, Golder W, Brandt J, Rudwaleit M, Listing J, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 2003; 48: 112636.
  • 3
    Maksymowych WP, Inman RD, Salonen D, Dhillon SS, Krishnananthan R, Stone M, et al. Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of spinal inflammation in ankylosing spondylitis. Arthritis Rheum 2005; 53: 5029.
  • 4
    De Vlam K, Mielants H, Verstaete KL, Veys EM. The zygapophyseal joint determines morphology of the enthesophyte. J Rheumatol 2000; 27: 17329.
  • 5
    Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 3618.
  • 6
    Van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al, and the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52: 58291.
  • 7
    Lambert RG, Salonen D, Rahman P, Inman RD, Wong RL, Einstein SG, et al, for the M03–606 Study Group. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2007; 56: 400514.
  • 8
    Inman R, Shojania K, Keystone E, Haraoui B, Mitchell C, Maksymowych W. Canadian evaluation of low dose infliximab in ankylosing spondylitis (CANDLE) [abstract]. J Rheumatol 2008; 56: 12134.
  • 9
    Garrett S, Jenkinson T, Kennedy G, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis disease activity index. J Rheumatol 1994; 1: 228691.
  • 10
    Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 2281−5.
  • 11
    Rennie WJ, Dhillon SS, Conner-Spady B, Maksymowych WP, Lambert RG. MRI assessment of spinal inflammation in ankylosing spondylitis: standard clinical protocols may omit inflammatory lesions in thoracic vertebrae. Arthritis Rheum (in press).
  • 12
    Baraliakos X, Landewe R, Hermann KG, Listing J, Golder W, Brandt J, et al. Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging. Ann Rheum Dis 2005; 64: 7304.
  • 13
    Appel H, Loddenkemper C, Grozdanovic Z, Ebhardt H, Dreimann M, Hempfing A, et al. Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis. Arthritis Res Ther 2006; 8: R143.